SSRIs: First Line Medications for Pediatric Anxiety and Depression

Drug (Brand)	FDA Approval	Formulations	Dosing	Pharm. Props.	Side Effects	Comments
Fluoxetine (Prozac)	MDD≥8yo, OCD≥7yo	Capsules: 10/20/40mg Tabs: 10/20/60mg Sol: 20mg/5mL	 Start 10mg QD (5mg/day for younger) Initialtarget 20mg QD Monthly increments/ decrements 10-20mg FDA Max 60mg/day (20- 30mg/day for younger children) 	 Long half-life (days) Out of system 1 m after stopping Strong P450 interaction (2D6, 2C19 inhibitor) 	SAME FOR ALL SSRIs: COMMON: • Nausea • Headaches • Dry mouth • Fatigue • Diarrhea • Constipation • Sweating • Sexual side effects • Activation/anxiety RARE: • Increase suicidal ideation (<u>not</u> completed suicide) • Hypo/mania	 ALL SSRIs: Usually takes 2-4 weeks to see effects; 4-8 weeks to see full effects Good for nonadh. pts due to long T ½ Discontinuation symptoms less likely More potential for drug-drug interactions
Sertraline (Zoloft)	OCD≥6yo	Tabs: 25/50/100mg Sol: 20mg/mL	 Start 25mg QD; 12.5 mg for younger children Initial target ~50mg QD Monthly increments/ decrements 25-50 mg FDA Max 200mg/day 	 Medium half-life (1 day) Out of system 1 week after stopping Weak P450 interaction 		 Unlikely to have drug- drug interactions May have discontinuation symptoms; taper off
Escitalopram (Lexapro)	MDD≥12yo GAD <u>></u> 7	Tabs: 5/10/20mg Sol: 5mg/5mL	 Start 5 mg QD, Initialtarget ~10mg QD Monthly increments/decrements 5- 10mg FDA Max 20mg/day 	 Medium half-life (1 day) Out of system 1 week after stopping No P450 interaction 	EXTREMELY RARE: • Seizures (OD) • Serotonin syndrome	 Unlikely to have drug- drug interactions May have discontinuation symptoms; taper off

03/24

Other Medications Used for Pediatric Anxiety and Depression

Drug (Brand)	Class	FDA approval	Formulations	Dosing	Pharm Properties	Side effects	Comments
Citalopram (Celexa)	SSRI	None in child/ adols.	Tabs: 10/20/40mg Sol: 10mg/5mL	 Start 10mg QD, initial target 20mg QD Monthly in/decrements 10-20mg Max 40mg/day 	 Medium half-life (>1d) P450 interaction weak 	Same as SSRIs PLUS: QT prolongation 	 Rarely used in children due to QT prolongation Unlikely to have drug-drug interactions May have discontinuation symptoms; taper off
Fluvoxamine (Luvox)	SSRI	OCD≥8yo	Tabs: 25/50/100mg	 Start 25mg QHS, initial target 50mg/day; BID dosing 25-50mg in/decrement Max 200mg/day up to 11yo, 300mg/day 11+yo 	 Short half-life (15h) P450 interaction Strong 	Same as SSRIs	 Used only for OCD BID dosing More likely to have drug-drug interactions Likely to have discontinuation symptoms; taper slower
Venlafaxine (Effexor)	SNRI	None in child/ adols.	Tabs: 25/37.5/50/75/100mg ER Caps: 37.5/75/150mg ER Tabs: 37.5/75/150/225mg	 Use ER formulations Start 37.5mg QD, initial target 75mg/day 37.5-75mg in/decrements FDA Max 225mg/day 	 Short half life (5 h parent, 11h active metab) Weak P450 interaction 	Same as SSRIs Increase diastolic BP at higher doses 	 IR needs BID dosing and is difficult to discontinue; taper very slowly ER formulations recommended Less likely to have drug-drug interactions
Duloxetine (Cymbalta)	SNRI	GAD ≥ 7yo	Caps:20/30/40/60mg	 Start 30mg QD, initial target 30 mg 30mg in/decrements Usually given as BID FDA Max 120mg/day 	 Medium half-life (12 hours) Moderate P450 interaction 	Same as SSRIs	 QD-BID dosing May be more difficult to wean off Do not open cap More likely to have drug-drug interactions Analgesic effect in a dults
Bupropion (Wellbutrin)	DNRI	None in child/ adols.	Tabs: 75/100mg (TID) ER Tabs (12h): 100/150/200/ 300mg (BID) XL tabs (24h): 150/300 (QD)	 Start 150mg XL daily, increase after 1-2 weeks to 300 mg XL FDA Max 450mg/day 	 Medium half-life (21 hours) Strong P450 interaction 	Same as SSRIs <u>PLUS</u> 1.Lowers seizure threshold 2.Lower likelihood of sexual side effects	 XL form preferred as QD Relative contraindication eating disorders, ETOH abuse Used for smoking cessation, 4th line ADHD (12+) Not effective for anxiety; may worsen More likely to have drug-drug interactions